Great news. These findings will influence the importance given to the newer drugs as well (such as Abiraterone acetate), which do not make part of the protocols of the patients/cases used in the trials but have proven effectiveness with lesser side effects.
I hope institutions like NCCN will alter their guidelines and introduce newer measures regarding HT, based on truthful results like these.
Here is the abstract of the trials;
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=77775
Joined: Nov 2010
NCCN may alter their guidelines
Arthur
Great news. These findings will influence the importance given to the newer drugs as well (such as Abiraterone acetate), which do not make part of the protocols of the patients/cases used in the trials but have proven effectiveness with lesser side effects.
I hope institutions like NCCN will alter their guidelines and introduce newer measures regarding HT, based on truthful results like these.
Here is the abstract of the trials;
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=77775
Thanks for posting the article.
VG